Here's a classic biotech market puzzle for you: Nasus Pharma Ltd. (NSRX) announced what looks like genuinely good news on Monday—positive Phase 2 data for its experimental EpiPen rival—and its stock promptly fell off a cliff, hitting a new 52-week low. Shares were down a brutal 43.6% to $2.82 by the afternoon. Sometimes the market reacts to data in ways that seem, well, allergic to logic.
The news itself was about NS002, the company's investigational intranasal epinephrine powder for treating severe allergic reactions (anaphylaxis). The topline results from the Phase 2 study showed the powder has the potential to beat the performance of the ubiquitous EpiPen. Specifically, it worked faster.
The key metric here is the time to reach a therapeutic epinephrine threshold in the blood (100 pg/mL). The median time for NS002 was 1.69 minutes. For the EpiPen? More than double that, at 3.42 minutes. By the 10-minute mark, roughly 95% of the participants who got the nasal spray had hit that critical level. That's the kind of data that, in theory, should make investors interested in a product aiming to disrupt a market dominated by a single, injectable device.
The Curious Case of the Sinking Stock
So, why the epic sell-off? Welcome to the often-perverse world of biotech investing. The stock actually surged in premarket trading, hitting a high of $7.29 right after the data drop. Then it reversed course dramatically. This has all the hallmarks of a "sell the news" event. Traders who bought on anticipation of good data simply cashed out once it was confirmed, creating a wave of selling pressure that overwhelmed any new buying interest.
There's also the nuance of the data itself. While the core speed-to-threshold story is strong, some investors might be comparing Monday's final results to very promising interim data released back in January. That earlier peek showed 91% of NS002 subjects hitting the threshold at the 5-minute mark, compared to 67% for EpiPen. Monday's final data showed 88.4% for NS002 versus 64.6% for EpiPen at 5 minutes—still a meaningful advantage, but a slight step down from the interim figures.
Similarly, the time to peak plasma concentration (Tmax) in the final data was a median of 15 minutes for NS002, beating EpiPen's 19.8 minutes. The January interim data had shown an even faster Tmax of 10.8 minutes. Again, the final numbers are good and show an improvement over the standard of care, but they may not have exceeded the already-high expectations set by the earlier snapshot.
The Path Forward and the Safety Story
The study involved 50 healthy adults with a history of allergies. Importantly, NS002 demonstrated a favorable safety profile with no serious adverse events reported, and it triggered a comparable bodily response to the EpiPen across all participants. For a product meant to be used in emergency situations, safety and reliability are just as important as speed.
The next big step is a pivotal study, which the company aims to start in the fourth quarter of 2026. That study will be the major test to confirm these Phase 2 findings and pave the way for a potential market approval. For biotech investors, that's now the date circled on the calendar—the next major catalyst that will determine if this fast-acting nasal powder can truly become a commercial reality.
For now, the market has rendered its verdict on this data release, and it was harsh. It's a reminder that in biotech, even good news can be punished if it doesn't massively exceed expectations or if traders are simply ready to take profits. Nasus Pharma has shown its product could be a faster, needle-free alternative for a life-threatening condition. On Monday, the market decided that wasn't enough to keep the stock from hitting a new low.
